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Abstract
Background: The relationship between cardiac enzyme (CE) release following coronary artery
bypass surgery (CABG) and medium term outcome is unclear. We sought to determine the
relationship between post-operative CE release and one-year survival following isolated CABG.
Methods:  Over three years 3,024 consecutive patients underwent isolated CABG. Patient
characteristics were prospectively recorded in a cardiac surgical database. CE release, taken as the
highest single measurement recorded in the first 24 hours post-op, was abstracted from an
electronic archive. All cause mortality was taken from a national registry of deaths.
Results: Data were complete for 2,860 (94.6%) patients. CK-MB isoenzyme (reference range 5–
24 U/l) was recorded in 2,568 (89.8%), total CK in 292 (10.2%).
CE release three or more times the upper limit of the reference range (ULR) were recorded in
498 (17.4%) patients, 163 (5.7%) patients had CE more than six times ULR. There were 122 deaths
(4.3%). Cox proportional hazards analysis showed that CE release 3–6 times ULR (adjusted HR 2.1
[95% CI: 1.6 to 2.6], p = 0.002) and CE release six or more times the ULR (adjusted HR 5.0 [95%
CI: 4.5 to 5.4], p < 0.001) were independently associated with increased one-year mortality.
Conclusion: Cardiac enzyme release following CABG is associated with increased one-year all-
cause mortality. The definition of peri-operative myocardial infarction following CABG should
include elevation of CK-MB three or more times the upper limit of normal.
Background
Myocardial necrosis causing release of cardiac enzymes
(CE) following otherwise uncomplicated percutaneous
coronary intervention has been associated with increased
medium term mortality [1,2]. Myocardial necrosis occurs
frequently in patients undergoing cardiac surgery. Puta-
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tive mechanisms of cardiac myonecrosis include diffuse
ischaemic injury during cardiopulmonary bypass, reper-
fusion injury, systemic inflammatory activation [3],
embolisation of atheromatous material during coronary
manipulation [4], and early graft occlusion [5], as well as
atrial cannulation and left ventricular venting [6].
Defining peri-operative myocardial infarction following
cardiac surgery has proven problematic due to the diffi-
culty in interpreting pain, electrocardiographic (ECG),
and haemodynamic changes in the early post operative
phase. Peri-operative ECG changes such as T wave inver-
sion, left or right bundle branch block, and new Q waves
have poor sensitivity and specificity for myocardial infarc-
tion [7-9], and appear not to be associated with reduced
medium and long term survival [9,10]. Cardiac specific
biochemical markers of myocardial injury are attractive
surrogates for clinical outcomes following cardiac surgery,
but lack robust thresholds for association with a diagnosis
of myocardial infarction and reduced survival [11]. The
most recent European Society of Cardiology/American
College of Cardiology joint guideline did not specify
threshold values of post-operative cardiac enzyme release
that defined myocardial infarction following coronary
artery bypass graft (CABG) surgery [12].
The current consensus among cardiac surgeons and cardi-
ologists is that post CABG CK-MB elevation of least 5
times the upper limit of reference range (ULR) marks the
threshold of prognostic significance [13]. However con-
siderable variation exists between the threshold values of
post CABG CK-MB release and subsequent mortality
observed among patients recruited in randomised con-
trolled trials [14,15], and unselected registries [8,16,17].
The clinical implications of recently revised diagnostic cri-
teria for myocardial infarction have been recognised and
the need for prognostic evaluation of peri-operative CE
release specifically emphasised [18,19].
We sought to determine the association between CE
release and survival at one-year, and to identify pre-oper-
ative predictor variables associated with increased CE
release following isolated CABG.
Methods
Patient population and data
An observational cohort study was performed. Using a
prospectively recorded cardiac surgical database we iden-
tified 3,024 consecutive patients, undergoing isolated
CABG between 1st January 1999 and 31st December 2001
at the Cardiothoracic Centre-Liverpool. Patients undergo-
ing surgery that involved heart valve repair or replace-
ment, resection of a ventricular aneurysm or other surgical
procedure were not included. The study was approved by
the local ethical committee.
All data were collected prospectively during the patient
admission as part of routine clinical practice (see Table 1).
Data collection methods and definitions have been
described in detail previously [20].
Cardiac enzyme data
During the study period it was our practice to routinely
request cardiac enzymes on admission to the intensive
care unit and on the morning of the first post operative
day. All assays were performed at 37°C. The assays used
were CK-MB immuno assay (Roche, reference range 5–24
U/l at 37°C) and total CK (Roche, reference range <190
U/l in men, <167 U/l in women at 37°C). CE results for
the first 24 hours post-op were taken from a routinely
recorded electronic clinical biochemistry archive, blind to
survival and other clinical data. When more than one CE
result existed the highest value of CK-MB isoenzyme was
selected in preference to the highest value of total CK.
One-year mortality data
Patient records were linked to the National Strategic Trac-
ing Service (NSTS), which records all-cause mortality in
the United Kingdom. To establish current vital status, at
one-year of follow-up, patients were matched to the NSTS
based on patient name, National Health Service unique
number, date of birth, gender, and postcode.
Statistics
Continuous variables were not normally distributed and
are shown as median with 25th and 75th percentiles. Cat-
Table 1: Patient characteristics
Study Population (n = 3,024)
Age at operation (years) 64.3 (58.4 to 70.0)
Female sex (%) 19.9
Body mass index (kg/m2) 27.6 (25.3 to 30.4)
Angina class IV (%) 32.9
Current smoker (%) 15.8
Previous myocardial infarction (%) 44.2
Diabetes (%) 17.6
Hypercholesteroleamia (%) 83.8
Hypertension (%) 55.3
Peripheral vascular disease (%) 13.8
Cerebrovascular disease (%) 8.2
Renal dysfunction (%) 2.7
Respiratory disease (%) 31.6
Ejection fraction <30% (%) 8.7
Three-vessel disease (%) 81.3
Left main stenosis >50% (%) 20.1
Prior cardiac intervention (%) 5.1
Prior cardiac surgery (%) 2.5
Urgent procedure (%) 16.9
Emergent procedure (%) 1.4
Continuous variables are shown as median with 25th and 75th 
percentiles.
Categorical variables are shown as a percentage.Journal of Cardiothoracic Surgery 2006, 1:20 http://www.cardiothoracicsurgery.org/content/1/1/20
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egorical data are shown as percentages. Deaths occurring
as a function of time, at one-year of follow-up were
described using the product limit methodology of Kaplan
and Meier [21]. Cox proportional hazards analysis was
used to identify independent risk factors for increased
one-year mortality and to calculate risk adjusted Kaplan-
Meier survival curves [22]. Multivariate logistic regression
was used to identify independent preoperative risk factors
for CE release above the threshold level associated with
increased one-year mortality. The C statistic (equivalent to
the area under the receiver operating characteristic curve)
and Hosmer-Lemeshow goodness-of-fit statistic were cal-
culated to assess the performance and calibration of the
logistic model respectively [23]. All variables listed in
Table 1 were included as potential risk factors in both the
Cox proportional hazards and logistic regression analyses.
In all cases a p value < 0.05 was considered significant. All
statistical analysis was performed with SAS for Windows
Version 8.2.
Results
Patient characteristic data were complete for all 3,024
patients (Table 1). Follow up for survival up to and
including 31st December 2002 was complete. Cardiac
enzymes were recorded in 2,860 (94.6%) who were
included in the analysis. Patients without CE results (n =
164) did not have statistically significant differences in
baseline characteristics compared to patients with CE
results, and had 3% one-year mortality.
Among the 2,860 patients with CE results, 2,568 (89.8%)
had CK-MB isoenzyme and 292 (10.2%) total CK only
performed within the first 24 hours post-op. The median
CK-MB iso-enzyme result was 36 U/l (25th and 75th per-
centiles: 24 to 60 U/l). The median total CK was 248 U/l
(25th and 75th percentiles: 213 to 285) for men, and 247
U/l (25th and 75th percentiles: 199–283) for women. Four
hundred and ninety eight (17.4%) patients had cardiac
enzymes three or more times the ULR. Two hundred and
twenty nine (8.0%) patients had CE five or more times the
ULR. One hundred and sixty three (5.7%) patients had CE
more than six times the ULR, while 59 (2.1%) had cardiac
enzymes ten or more times the ULR.
There were 122 (4.3%) deaths during the first post-opera-
tive year among the 2,860 patients with CE results. Cox
proportional hazards analysis revealed that CE release >6
times the ULR (adjusted hazard ratio (HR) 5.0 [95% CI:
4.5 to 5.4], p < 0.001) and CE release 3 to 6 times the ULR
(adjusted HR 2.1 [95% CI: 1.6 to 2.6], p = 0.002) were
independent predictors of increased mortality at one-year.
The crude mortality was identical for cardiac enzymes 3 to
5 times, and 5 to 6 times the ULR at 4.8%. When CE
release 3 to 5 times the ULR was offered to the model the
magnitude of association with increased one-year mortal-
ity was not substantially changed (adjusted HR 1.9, p =
0.015) confirming that the association for the group of
patients with CE release 3 to 6 times the ULR is not solely
driven by the highest values of CK-MB in this band.
Other independent risk factors for one-year mortality
included poor ejection fraction (< 30%), increasing age,
pre-operative renal dysfunction, peripheral vascular dis-
ease, prior cardiac surgery, emergency surgery, and female
sex (Table 2). Other variables listed in Table 1 were not
found to be associated with increased mortality.
The relationship between CE release and death within the
first post-operative year are displayed in the risk adjusted
survival curves (Figure 1). The independent association
between increased mortality and CE release 3 to 6 times
the ULR and CE release >6 times the ULR was unaffected
by restricting analysis to patients with CK-MB isoenzyme
results, with adjusted HR 2.3 (p = 0.001) and adjusted HR
6.2 (p < 0.001) respectively.
All the patient characteristics listed in Table 1 were offered
to a multivariate logistic regression analysis. We found
that female sex, extent of coronary disease, peripheral vas-
cular disease, hypercholesterolaemia, and hypertension
Table 2: Independent risk factors for increased one-year mortality
Hazard Ratio 95% Confidence Intervals p Value
CE release >6 times the ULR 5.0 4.5 to 5.4 <0.001
Ejection fraction <30% 3.1 2.7 to 3.5 <0.001
Age at operation * 1.06 1.03 to 1.08 <0.001
Renal dysfunction 2.6 2.0 to 3.2 <0.001
Peripheral vascular disease 2.1 1.7 to 2.5 0.002
CE release 3 to 6 times the ULR 2.1 1.6 to 2.6 0.002
Prior cardiac surgery 2.9 2.2 to 3.7 0.006
Emergent procedure 2.8 2.0 to 3.6 0.007
Female sex 1.5 1.1 to 1.9 0.041
CE, Cardiac enzyme; ULR, Upper limit of reference range.
* per unit increase.Journal of Cardiothoracic Surgery 2006, 1:20 http://www.cardiothoracicsurgery.org/content/1/1/20
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were independent predictors of CE release three or more
times the ULR (Table 3).
Discussion
This study shows a highly statistically significant, and clin-
ically meaningful independent association between CK-
MB release within the first 24 hours following isolated
CABG surgery and increased mortality within the first
post-operative year. Although the highest risk of death is
associated with greater CE release we have demonstrated
that the independent association between CE release and
death is not confined to the few individuals with highest
values of CE release. To the best of our knowledge this is
the first study to show that modest levels of post-CABG CE
release 3 to 6 times the ULR are independently associated
with higher one-year mortality.
CE release three or more times the ULR occurred in
approximately one in six of the patients in this study. Such
patients were more frequently female, had more target
vessels, and peripheral vascular disease. These associa-
tions may be due to more challenging surgical anatomy
[24], and more widespread and advanced atherosclerotic
disease respectively. However the low c statistic (0.61) for
the multivariate pre-operative characteristic model, sug-
gests that a significant proportion of the risk of CE release
three or more times the ULR may be accounted for by
other variables not included in the present analysis.
We chose to use a CK-MB immuno assay as this had been
historical practice at the Cardiothoracic Centre-Liverpool.
Although CK-MB estimation remains the most widely
used post revascularisation assay our results may have
been strengthened had we used more sensitive and spe-
cific enzymes assays such as troponin T or I [25,26]. How-
ever recent comparisons between CK-MB and tropoinin I
in predicting irreversible myocardial injury, detected by
cardiac magnetic resonance imaging, following CABG did
not suggest that peak troponin I was superior to peak
CKMB [27]. Although troponin assays are more closely
associated with early graft occlusion [28,29], further
investigation is required to confirm their independent
prognostic superiority for survival following surgical re-
vascularisation procedures.
Earlier studies suggested that the association between
increased medium term mortality and peri-operative CE
release following CABG surgery was confined to those
individuals with CE release >5 times the ULR [9,14,15], or
CE release >10 times the ULR [16], and that an independ-
ent association between CE release 3 to 5 times the ULR
and mortality was only apparent after long term follow up
[17]. Our data shows that although CE release >6 times
the ULR is more strongly associated with death in the first
post-operative year, lower levels of CE release are also
associated with increased one-year mortality. The discrep-
ancy between the findings in this and earlier studies may
in part be explained by a more inclusive and completely
described cohort, and lower heterogeneity in the timing
and type of cardiac enzyme assay used in our study.
Both Klatte [14] and Costa [15] found CK-MB release 5
times or more the ULR was associated with an increased
risk of mortality at 6-months and one-year respectively.
Table 3: Independent risk factors for cardiac enzyme release >= 3 times the ULR
Odds Ratio 95% Confidence Intervals p Value
Female sex 1.72 1.37 to 2.15 <0.001
Triple-vessel disease 1.48 1.13 to 1.94 0.005
Peripheral vascular disease 1.39 1.07 to 1.81 0.013
Hypercholesterolaemia 1.39 1.04 to 1.86 0.024
Hypertension 1.24 1.02 to 1.52 0.034
ULR, Upper limit of reference range.
C 0.61, Lemeshow-Hosmer goodness of fit P = 0.76
Adjusted one-year survival following coronary artery bypass  surgery for cardiac enzyme release <3 times, 3 to 6 times,  and >6 times the ULR Figure 1
Adjusted one-year survival following coronary artery bypass 
surgery for cardiac enzyme release <3 times, 3 to 6 times, 
and >6 times the ULR. Data adjusted for risk factors listed in 
table 2.
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Both studies however, originated from randomised con-
trol trials and excluded high-risk patients such as left main
stem stenosis, impaired left ventricular function, cere-
brovascular disease, and significant renal impairment.
Our own study population, however, included 20.1%
with left main stem stenosis, 8.7% with ejection fraction
<30%, 8.2% with cerebrovascular disease, and 2.7% with
renal dysfunction (serum creatinine >200 mmol and/or
dialysis support). These differences in patient characteris-
tics could help explain the differences between these stud-
ies.
The work by Brener and associates [16] implied that only
patients with large cardiac enzyme release (>10 times
ULR) had an association with increased mortality. No
association between >5 times ULR and mortality was
found, which is at odds with the studies by Klatte [14] and
Costa [15], and differs significantly from our own find-
ings.
Marso and colleagues [17] found similar results to our
findings, demonstrating the importance of cardiac
enzyme release >3 times ULR on increased mortality post-
CABG. This association was still evident even after 5-years
follow-up. The study recommended the routine data col-
lection of CK-MB following CABG to aid in long-term risk
assessment, which we would agree with.
The editorial by Mahaffey and Alpert [18] stressed the
importance of developing a consensus about what consti-
tutes a myocardial infarction post-CABG, especially since
the joint European Society of Cardiology and American
College of Cardiology Committee provided no standard
criteria due to the lack of definitive data [12]. Our findings
and recent other studies [14,15,17] provide such data,
which will help lead toward such a consensus opinion.
The message from this study is clear: myocardial necrosis
following CABG is undesirable. We have demonstrated
that levels of CE release previously thought to be innocu-
ous are independently associated with increased one-year
mortality. CK-MB release three or more times above the
upper limit of reference range, measured within the first
24 hours following isolated CABG should be regarded as
prognostically significant and may form the basis for a
simplified definition of peri-operative myocardial infarc-
tion following coronary artery bypass surgery.
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